Aladdin Healthcare Technologies has developed a fully automated deep learning process for the detection of COVID-19 infection. The technology can prevent the false diagnoses of laboratory tests and differentiate pneumonia from COVID-19 cases.
In a paper published in the journal of the Institute of Electrical and Electronics Engineers, Aladdin Healthcare Technologies discuss the importance of developing alternatives to laboratory testing. Laboratory tests, for example, using reverse transcription polymerase chain reaction (RT-PCR), have so far been the gold standard for detecting COVID-19, but may produce false negative results.
During the COVID-19 pandemic, a lack of testing resources may delay diagnosis and treatment. Under such circumstances, chest CT imaging has become a valuable tool for both the diagnosis and prognosis of COVID-19 patients. The method minimises the requirements for manual labelling of CT images and at the same time allows accurate infection detection.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: “Based on the promising results obtained qualitatively and quantitatively, we can envisage a wide deployment of our developed technique in large-scale clinical studies.
“This demonstrates the advanced capabilities of Aladdin to deliver best in class A.I. solutions even in emergency situations. The solution will be delivered to the Innovative Medicines Initiative (IMI) as part of the DRAGON project to combat COVID-19”.
About Aladdin Healthcare Technologies
Aladdin Healthcare Technologies is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process.
The main focus of Aladdin is aged related disease, including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to gather targeted data, including genome, tabular, MRI, PET, cognition, and other lifestyle data. These datasets are then analysed by their award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to diagnose aged related diseases more accurately and efficiently.
This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, Aladdin’s AI drug discovery platform will be used to by pharmaceutical companies to speed up drug development, clinical trials, and predict outcomes more accurately.